Literature DB >> 25922684

Vaccine development and new attempts of treatment for ragweed allergy.

David El-Qutob1.   

Abstract

Ragweeds are flowering plants in the genus Ambrosia in the aster family, Asteraceae. They are distributed in the tropical and subtropical regions of the New World, especially North America. Short ragweed is the most important weed. The ragweed flowering occurs late in the summer and the pollination period extends from the beginning of August to mid-October. Sensitization to ragweed pollen has risen in United States in the past decade and probably worldwide. The major allergenic compound in the pollen has been identified as Amb a 1. Ragweed allergies usually cause allergic rhinitis and asthma. Ragweed allergic patients may show signs of oral allergy syndrome caused by crossreactivity between ragweed allergens and food allergens. In the present article, an update about vaccine development and new knowledge for ragweed allergy is exhaustively revised.

Entities:  

Keywords:  immunotherapy; pollen; ragweed

Year:  2015        PMID: 25922684      PMCID: PMC4406916          DOI: 10.1177/2051013614565354

Source DB:  PubMed          Journal:  Ther Adv Vaccines        ISSN: 2051-0136


  41 in total

Review 1.  Local allergic rhinitis: concept, pathophysiology, and management.

Authors:  Carmen Rondón; Paloma Campo; Alkis Togias; Wytske J Fokkens; Stephen R Durham; Desmond G Powe; Joaquim Mullol; Miguel Blanca
Journal:  J Allergy Clin Immunol       Date:  2012-04-18       Impact factor: 10.793

2.  Associations between grass and weed pollen and emergency department visits for asthma among children in Montreal.

Authors:  Léa Héguy; Michelle Garneau; Mark S Goldberg; Marie Raphoz; Frédéric Guay; Marie-France Valois
Journal:  Environ Res       Date:  2008-02       Impact factor: 6.498

3.  Humoral and cellular cross-reactivity between Amb a 1, the major ragweed pollen allergen, and its mugwort homolog Art v 6.

Authors:  Beatrice Jahn-Schmid; Michael Hauser; Nicole Wopfner; Peter Briza; Uwe E Berger; Riccardo Asero; Christof Ebner; Fatima Ferreira; Barbara Bohle
Journal:  J Immunol       Date:  2011-12-28       Impact factor: 5.422

4.  Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I.

Authors:  P-J Bousquet; S Chinn; C Janson; M Kogevinas; P Burney; D Jarvis
Journal:  Allergy       Date:  2007-03       Impact factor: 13.146

Review 5.  Allergy immunotherapy: what is the evidence for cost saving?

Authors:  Cheryl S Hankin; Linda Cox
Journal:  Curr Opin Allergy Clin Immunol       Date:  2014-08

Review 6.  Recent advances in immunotherapy for allergic diseases.

Authors:  David El-Qutob; Gemma Mencia; Enrique Fernandez-Caldas
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2014-01

7.  Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.

Authors:  Piyush Patel; Tom Holdich; Karl J Fischer von Weikersthal-Drachenberg; Birgit Huber
Journal:  J Allergy Clin Immunol       Date:  2013-07-16       Impact factor: 10.793

Review 8.  Pollen-food syndromes associated with weed pollinosis: an update from the molecular point of view.

Authors:  M Egger; S Mutschlechner; N Wopfner; G Gadermaier; P Briza; F Ferreira
Journal:  Allergy       Date:  2006-04       Impact factor: 13.146

9.  [Prevalence of ragweed hayfever in the south and east of the greater Lyon region in 1993].

Authors:  C Déchamp; M Le Gal; P Deviller
Journal:  Allerg Immunol (Paris)       Date:  1995-11

10.  Safety and tolerability of a short ragweed sublingual immunotherapy tablet.

Authors:  Hendrik Nolte; Niran Amar; David I Bernstein; Bobby Q Lanier; Peter Creticos; Gary Berman; Amarjot Kaur; Jacques Hébert; Jennifer Maloney
Journal:  Ann Allergy Asthma Immunol       Date:  2014-05-14       Impact factor: 6.347

View more
  1 in total

1.  Sequence conservation predicts T cell reactivity against ragweed allergens.

Authors:  J Pham; C Oseroff; D Hinz; J Sidney; S Paul; J Greenbaum; R Vita; E Phillips; S Mallal; B Peters; A Sette
Journal:  Clin Exp Allergy       Date:  2016-07-26       Impact factor: 5.018

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.